In support of this, the TLR2/4 dual ligand CS1 has been recently awarded the orphan drug designation by the European Medicines Agency (EMA) for the treatment of CDH (https://ec.europa.eu/health/documents/community-register/html/o2801.htm). The gene discussed is TLR2; the disease is congenital diaphragmatic hernia.